니온크 테크놀로지스 홀딩스(NTHI)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.26 (-4.40%), 시가총액 $138.91M.
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009.
니온크 테크놀로지스 홀딩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
니온크 테크놀로지스 홀딩스의 현재 주가는 $3.26 (-4.40%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
니온크 테크놀로지스 홀딩스의 시가총액은 약 $138.91M입니다.
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.